Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0NO5E
|
||||
| Former ID |
DNC010469
|
||||
| Drug Name |
Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [530752] | ||
| Formula |
C19H16N2O3S
|
||||
| Canonical SMILES |
CCOC(=O)NC1=NC(=C(S1)C(=O)C2=CC=CC=C2)C3=CC=CC=C3
|
||||
| InChI |
1S/C19H16N2O3S/c1-2-24-19(23)21-18-20-15(13-9-5-3-6-10-13)17(25-18)16(22)14-11-7-4-8-12-14/h3-12H,2H2,1H3,(H,20,21,23)
|
||||
| InChIKey |
VMTZCTQCFMWSEO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A3 receptor | Target Info | Inhibitor | [530752] | |
| Adenosine A1 receptor | Target Info | Inhibitor | [530752] | ||
| Adenosine A2b receptor | Target Info | Inhibitor | [530752] | ||
| Adenosine A2a receptor | Target Info | Inhibitor | [530752] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addictionhsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholismhsa04015:Rap1 signaling pathway | |||||
| Parkinson's disease | |||||
| Alcoholism | |||||
| Pathway Interaction Database | C-MYB transcription factor networkhif2pathway:HIF-2-alpha transcription factor network | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.